Advertisement
Research Article| Volume 185, 109225, March 2022

Comparative risk of serious hypoglycemia among persons dispensed a fluoroquinolone versus a non-fluoroquinolone antibiotic

  • Darcy E. Ellis
    Correspondence
    Corresponding author at: 2031 Martha St, Philadelphia, PA 19125, USA.
    Affiliations
    Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
    Search for articles by this author
  • Rebecca A. Hubbard
    Affiliations
    Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
    Search for articles by this author
  • Allison W. Willis
    Affiliations
    Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

    Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
    Search for articles by this author
  • Athena F. Zuppa
    Affiliations
    Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

    Department of Anesthesiology and Critical Care, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA
    Search for articles by this author
  • Theoklis E. Zaoutis
    Affiliations
    Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

    Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
    Search for articles by this author
  • Sean Hennessy
    Affiliations
    Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
    Search for articles by this author
Published:February 02, 2022DOI:https://doi.org/10.1016/j.diabres.2022.109225

      Abstract

      Aim

      Fluoroquinolone antibiotics have been implicated in cases of metabolic adverse events. This study investigated the causal association between fluoroquinolones and serious hypoglycemia in those with and without diabetes.

      Methods

      We conducted a propensity score-matched cohort study using Optum claims data. We included adults dispensed an oral fluoroquinolone or comparator antibiotic between January 2000 and September 2015 for specific infections of interest. The outcome was serious hypoglycemia, defined using a validated algorithm. Conditional logistic regression was used to estimate odds ratios (ORs) in diabetes and non-diabetes cohorts after matching on propensity scores fitted using confounding variables of interest.

      Results

      Our cohort contained 119,112 individuals with diabetes and 917,867 individuals without diabetes exposed to a fluoroquinolone, matched 1:1 with a comparator. Matching produced balance (standardized mean difference < 0.1) on all variables included in the propensity score. The OR for the association between fluoroquinolones and serious hypoglycemia was 1.28 (95% confidence interval [CI]: 1.04–1.57) in the entire cohort, 1.30 (95% CI: 1.05–1.62) in individuals with diabetes, and 1.06 (95% CI: 0.53–2.13) in individuals without diabetes.

      Conclusion

      Fluoroquinolone users are at an increased risk of serious hypoglycemia relative to comparator antibiotic users. This association was evident only among persons diagnosed with diabetes.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Diabetes Research and Clinical Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kabbani S.
        • Hersh A.L.
        • Shapiro D.J.
        • Fleming-Dutra K.E.
        • Pavia A.T.
        • Hicks L.A.
        Opportunities to improve fluoroquinolone prescribing in the United States for adult ambulatory care visits.
        Clin Infect Dis. 2018; 67: 134-136
        • Hicks L.A.
        • et al.
        US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011.
        Clin Infect Dis. 2015; 60: 1308-1316
        • Hicks L.A.
        • Taylor T.H.
        • Hunkler R.J.
        U.S. outpatient antibiotic prescribing, 2010.
        N Engl J Med. 2013; 368: 1461-1462
        • Linder J.A.
        • Huang E.S.
        • Steinman M.A.
        • Gonzales R.
        • Stafford R.S.
        Fluoroquinolone prescribing in the United States: 1995 to 2002.
        Am J Med. 2005; 118: 259-268
      1. Determination That TEQUIN (Gatifloxacin) Was Withdrawn From Sale for Reasons of Safety or Effectiveness U.S.F.a.D. Administration, Editor; 2008. p. 52357–58.

        • Park-Wyllie L.Y.
        • Juurlink D.N.
        • Kopp A.
        • Shah B.R.
        • Stukel T.A.
        • Stumpo C.
        • et al.
        Outpatient gatifloxacin therapy and dysglycemia in older adults.
        N Engl J Med. 2006; 354: 1352-1361
        • Frothingham R.
        Glucose homeostasis abnormalities associated with use of gatifloxacin.
        Clin Infect Dis. 2005; 41: 1269-1276
      2. FDA. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. 2018; Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side.

        • Smith K.M.
        • Lomaestro B.M.
        What role do fluoroquinolone antimicrobial agents play in cardiac dysfunction and altered glycemic control?.
        J Pharm Pract. 2003; 16: 349-360
        • Berhe A.
        • et al.
        Ciprofloxacin and risk of hypolycemia in non-diabetic patients.
        J Med Case Rep. 2019; 13: 142
        • Singh P.
        • L' Esperance K.
        • Butler A.
        • Yenulevich E.
        • Malhotra S.
        • Glotzbecker B.
        Ciprofloxacin-associated hypoglycemia.
        Am J Ther. 2019; 26: e717-e718
        • Triplitt C.
        Drug interactions of medications commonly used in diabetes.
        Diabetes Spectrum. 2006; 19: 202-211
        • Graumlich J.F.
        • Habis S.
        • Avelino R.R.
        • Salverson S.M.
        • Gaddamanugu M.
        • Jamma K.
        • et al.
        Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.
        Pharmacotherapy. 2005; 25: 1296-1302
        • Lodise T.
        • Graves J.
        • Miller C.
        • Mohr J.F.
        • Lomaestro B.
        • Smith R.P.
        Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients.
        Pharmacotherapy. 2007; 27: 1498-1505
        • Schelleman H.
        • Bilker W.B.
        • Brensinger C.M.
        • Wan F.
        • Hennessy S.
        Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.
        Clin Pharmacol Ther. 2010; 88: 214-222
      3. Optum. Retrospective database analysis. 2013; Available from: https://www.optum.com/content/dam/optum/resources/productSheets/Retrospective-Database-Analysis.pdf.

        • Copp H.L.
        • Yiee J.H.
        • Smith A.
        • Hanley J.
        • Saigal C.S.
        Use of urine testing in outpatients treated for urinary tract infection.
        Pediatrics. 2013; 132: 437-444
        • Lee M.-T.
        • Lee S.-H.
        • Chang S.-S.
        • Lee S.-H.
        • Lee M.
        • Fang C.-C.
        • et al.
        Comparative effectiveness of different oral antibiotics regimens for treatment of urinary tract infection in outpatients: an analysis of national representative claims database.
        Medicine (Baltimore). 2014; 93: e304https://doi.org/10.1097/MD.0000000000000304
        • Suskind A.M.
        • Saigal C.S.
        • Hanley J.M.
        • Lai J.
        • Setodji C.M.
        • Clemens J.Q.
        Incidence and management of uncomplicated recurrent urinary tract infections in a national sample of women in the United States.
        Urology. 2016; 90: 50-55
        • Piccirillo J.F.
        • et al.
        Impact of first-line vs second-line antibiotics for the treatment of acute uncomplicated sinusitis.
        JAMA. 2001; 286: 1849-1856
        • Rothberg M.B.
        • et al.
        Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease.
        JAMA. 2010; 303: 2035-2042
        • Quan H.
        • Sundararajan V.
        • Halfon P.
        • Fong A.
        • Burnand B.
        • Luthi J.-C.
        • et al.
        Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.
        Med Care. 2005; 43: 1130-1139
        • Ginde A.A.
        • et al.
        Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits.
        BMC Endocr Disord. 2008; 8: 4
        • Austin P.C.
        An introduction to propensity score methods for reducing the effects of confounding in observational studies.
        Multivariate Behav Res. 2011; 46: 399-424
        • Austin P.C.
        Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.
        Stat Med. 2009; 28: 3083-3107
      4. National Diabetes Statistics Report 2020. 2020; Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf.

        • Boyanova L.
        • Mitov I.
        Antibiotic resistance rates in causative agents of infections in diabetic patients: rising concerns.
        Exp Rev Anti-Infect Ther. 2013; 11: 411-420